Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
14.37
+0.86 (6.37%)
At close: Jun 6, 2025, 4:00 PM
14.70
+0.33 (2.30%)
Pre-market: Jun 9, 2025, 4:00 AM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 342 employees as of December 31, 2024. The number of employees increased by 46 or 15.54% compared to the previous year.
Employees
342
Change (1Y)
46
Growth (1Y)
15.54%
Revenue / Employee
$622,278
Profits / Employee
-$379,289
Market Cap
1.71B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ARQT News
- 2 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 days ago - Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference - GlobeNewsWire
- 4 days ago - Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside - Seeking Alpha
- 10 days ago - Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 17 days ago - Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - GlobeNewsWire
- 24 days ago - New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - GlobeNewsWire
- 4 weeks ago - Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology - GlobeNewsWire
- 4 weeks ago - Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript - Seeking Alpha